Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038358 (gastric ulcer)
 5,179 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a double-blind study the influence of Pirenzepin on ulcer healing was studied in 28 in-patients with gastric ulcer under endoscopic control. The ulcer size was reduced by Pirenzepin significantly quicker, and the number of ulcers healed after three weeks treatment with Pirenzepin was significantly higher than under placebo. As to accompanying symptoms appetite stimulation was significantly more frequent with Pirenzepin compared to placebo. No patient complained of dryness of the mouth.
 ...
PMID:[Influence of pirenzepin on healing of gastric ulcer. A double blind study in in-patients (author's transl)]. 3 95

21 patients with peptic ulcers were treated with 2X25 mg Pirenzepin daily. A decrease in basal and Pentagastrin-stimulated HCl-secretion was found. Patients with duodenal ulcers (n = 12) or gastric ulcers (n = 9) became painless within 6 to 11 days. 18 ulcers healed under treatment with Pirenzepin. Patients with duodenal ulcer showed recovery sooner than patients with gastric ulcer. One year later recurrent ulcers were observed in 4 cases. Side-effects of Pirenzepin did not occur.
 ...
PMID:[Experiences with Pirenzepin in the therapy of peptic ulcers (author's transl)]. 52 96

1. The pharmacokinetics of pirenzepine (Gastrozepin) was studied after single and multiple oral administration in gastric ulcer and duodenal ulcer patients. 2. With a dose of 50 mg of pirenzepine, plasma levels reached a maximum 2 h after the administration in both groups (gastric ulcer patients: 57.2 +/- 31.8 ng/ml, duodenal ulcer patients: 48.0 +/- 18.0 ng/ml), and decreased bi-phasically with an elimination half-life (t1/2 beta) of 13.9 +/- 4.0 and 17.9 +/- 4.5 h, respectively. The area under the plasma level curve were 844 +/- 319 ng X h/ml and 663 +/- 151 ng X h/ml in the respective group. 3. The plasma levels of pirenzepine after multiple administration (50 mg was given as a loading dose, and thereafter 25 mg was given as a maintenance dose at an interval of 12 h for 7 days) maintained certain steady state levels from just after the start of administration. 4. It can be concluded that there is no significant difference in the pharmacokinetics of pirenzepine between gastric and duodenal ulcer patients. It can be judged that twice-daily administration of pirenzepine is enough for ulcer treatment.
 ...
PMID:Pharmacokinetics of pirenzepine in patients with gastric or duodenal ulcers. 367

In seventy-five out-patients with gastric and duodenal ulcer a comparative double-blind trial with pirenzepin against placebo was performed. The dose was 50 mg pirenzepin daily or placebo respectively, the duration of treatment being 4 weeks. The healing effect of pirenzepin in duodenal ulcer patients could be proven endoscopically and was statistically significant when compared with placebo (p less than or equal to 0.05). Strong evidence for the therapeutic efficacy of pirenzepin could be further demonstrated in both duodenal and gastric ulcer patients by measuring the marked reduction of ulcer size, even though statistical difference against placebo in gastric ulcers was not fully achieved. Pirenzepin was well tolerated by all patients, except for a mild case of diarrhoea which occurred in one patient. No patient complained of dryness of the mouth or of blurred vision.
 ...
PMID:Pirenzepin in gastric and duodenal ulcer: a double-blind trial. 701 85